Dr. Brufsky on Choosing When to do a Multiparameter Genomic Assay

Adam M. Brufsky, MD, PhD
Published Online: Saturday, Mar 11, 2017


Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses when to do a multiparameter genomic assay for a patient with early-stage breast cancer.

Brufsky advises all physicians to pre-screen their patients to determine their risk of recurrence before choosing whether to do a multiparameter genomic assay. 

Historically, physicians have done these tests to confirm their patient’s risk of recurrence, Brufsky explains, however, he advises not to do the testing for patients who are determined to have a low risk of recurrence during a pre-screening. If a patient cannot be classified as low risk, Brufsky explains that doing a multiparameter genomic assay is fine.

<<< View more from the 2017 Miami Breast Cancer Conference

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses when to do a multiparameter genomic assay for a patient with early-stage breast cancer.

Brufsky advises all physicians to pre-screen their patients to determine their risk of recurrence before choosing whether to do a multiparameter genomic assay. 

Historically, physicians have done these tests to confirm their patient’s risk of recurrence, Brufsky explains, however, he advises not to do the testing for patients who are determined to have a low risk of recurrence during a pre-screening. If a patient cannot be classified as low risk, Brufsky explains that doing a multiparameter genomic assay is fine.

<<< View more from the 2017 Miami Breast Cancer Conference

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: 15th Annual International Congress on the Future of Breast Cancer®Oct 06, 20172.0
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
Publication Bottom Border
Border Publication